Latest News and Press Releases

Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, October 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...

Longeveron Chief Science Officer and Chief Medical Officer selected as speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (Dec 8-10).

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy,...

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will...

New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive...

The C3i Center is proud to announce the appointment of Bobby Boursiquot, B.Sc., MBA, as Vice President of Commercialization.